CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.5% – What’s Next?

by · The Cerbat Gem

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price was down 0.5% during trading on Thursday . The stock traded as low as $44.60 and last traded at $45.19. Approximately 135,605 shares traded hands during trading, a decline of 91% from the average daily volume of 1,465,718 shares. The stock had previously closed at $45.40.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of recent research reports. Royal Bank of Canada reduced their price objective on shares of CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Piper Sandler restated an “overweight” rating and issued a $105.00 price target on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Rodman & Renshaw initiated coverage on CRISPR Therapeutics in a research note on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective on the stock. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, August 16th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $75.19.

Read Our Latest Stock Report on CRISPR Therapeutics

CRISPR Therapeutics Stock Performance

The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of -16.61 and a beta of 1.68. The business has a fifty day simple moving average of $47.44 and a 200 day simple moving average of $54.37.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter in the previous year, the firm posted ($0.98) EPS. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Riggs Asset Managment Co. Inc. increased its holdings in CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares during the period. Global Trust Asset Management LLC boosted its position in shares of CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Larson Financial Group LLC increased its stake in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares during the last quarter. NBC Securities Inc. raised its position in CRISPR Therapeutics by 257.6% during the first quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its stake in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles